Fortrea to Participate in Jefferies Global Healthcare Conference

Fortrea (FTRE), a leading global CRO, announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026, with a fireside chat and 1x1 meetings scheduled.

10/27/2026, 7:00 AM • GlobeNewswire

Kolaborasi Fortrea dan Omico untuk Mendorong Pengembangan Obat Onkologi Berbasis Biomarker

Fortrea, a leading global contract research organization, has partnered with Omico, Australia's precision oncology leader, to accelerate biomarker-driven cancer research. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve clinical trial site selection, patient recruitment, and access to biomarker-matched trials in Australia, leveraging Omico's database of over 23,000 consented patients and 1,600+ referring physicians.

10/23/2026, 12:58 PM • GlobeNewswire

Fortrea 與 Omico 攜手合作，推動生物標記主導的腫瘤藥物開發

Fortrea, a leading Contract Research Organization (CRO), has partnered with Omico, Australia's precision oncology screening platform, to accelerate biomarker-driven cancer clinical trials in Australia. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve trial planning, site selection, and patient recruitment, leveraging Omico's database of over 23,000 consented patients and referrals from 1,600+ clinicians across Australia.

10/23/2026, 12:58 PM • GlobeNewswire

Fortrea und Omico kooperieren zur Förderung der biomarkergestützten Entwicklung von Krebsmedikamenten

Fortrea, a leading global clinical research organization, has partnered with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven cancer drug development. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve study planning, patient recruitment, and access to biomarker-based clinical trials in Australia, leveraging Omico's database of over 23,000 patients and referrals from 1,600+ Australian physicians.

10/23/2026, 12:58 PM • GlobeNewswire

Collaboration entre Fortrea et Omico pour faire progresser le développement de médicaments oncologiques basés sur des biomarqueurs

Fortrea, a leading global contract research organization, has announced a collaboration with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven oncology drug development. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve clinical trial planning, site selection, and patient recruitment for targeted cancer therapies in Australia.

10/23/2026, 12:58 PM • GlobeNewswire

שיתוף פעולה בין Fortrea ל-Omico לקידום פיתוח תרופות אונקולוגיות המבוססות על סמנים ביולוגיים

Fortrea, a leading global clinical research organization, has announced a collaboration with Omico, Australia's leading precision oncology platform, to accelerate biomarker-driven oncology research. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve trial design, site selection, and patient recruitment, enabling faster access to relevant clinical trials for cancer patients based on their genomic profiles across Australia.

10/23/2026, 12:58 PM • GlobeNewswire

フォートリアとオミコ、バイオマーカー主導の抗がん剤開発推進に向けて提携

Fortrea, a leading clinical development CRO, has partnered with Omico, Australia's precision oncology screening organization, to accelerate biomarker-driven cancer clinical trials. The collaboration combines Fortrea's oncology trial expertise with Omico's PrOSPeCT platform to improve trial site selection, patient matching, and recruitment efficiency in Australia, with plans to expand globally.

10/23/2026, 12:58 PM • GlobeNewswire

포트리아와 오미코, 바이오마커 기반 항암 신약 개발 발전 위한 협력 추진

Fortrea, a leading clinical research organization, has partnered with Omico, Australia's precision oncology testing and clinical trial matching organization, to accelerate biomarker-based cancer research in Australia. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve patient-trial matching, enhance site selection efficiency, and expand access to precision oncology research globally.

10/23/2026, 12:58 PM • GlobeNewswire

Fortrea 与 Omico 携手，推进生物标志物导向的肿瘤药物开发

Fortrea, a leading global contract research organization, has partnered with Omico, Australia's precision oncology screening institution, to accelerate biomarker-driven cancer clinical trials. The collaboration combines Fortrea's oncology trial expertise with Omico's PrOSPeCT program—Australia's largest cancer genomics initiative—to improve patient matching, research center selection, and recruitment efficiency for precision oncology studies.

10/23/2026, 12:58 PM • GlobeNewswire

Fortrea Akan Mengakuisisi Unit Farmakologi Klinis dan Operasional Laboratorium Bionalitik dari Worldwide Clinical Trials

Fortrea has signed a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million. The acquisition includes bioanalytical laboratories in Austin, a 200-bed clinical pharmacology unit in San Antonio, and biospeci­men storage facilities in Pflugerville, Texas. This deal strengthens Fortrea's early-stage clinical development platform and integrated capabilities, while allowing Worldwide to focus on its faster-growing late-stage business across oncology, neuroscience, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

フォートリア、ワールドワイド・クリニカル・トライアルズから臨床薬理部門およびバイオアナリシスラボ事業を買収

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical lab in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and a biorepository facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase I through Phase IV trials, while allowing Worldwide to focus on its rapidly growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea, Worldwide Clinical Trials의 임상약리 유닛·생물분석 연구소 사업 인수

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and biospecimen storage facilities in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase 1 through Phase 4 trials and post-approval evidence generation, while allowing Worldwide to focus on its faster-growing late-stage clinical business in oncology, neuroscience, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea תרכוש את היחידה לפרמקולוגיה קלינית ואת פעילות המעבדה הביו-אנליטית של Worldwide Clinical Trials

Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in cash. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biological sample storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its rapidly growing late-stage development business in oncology, neuroscience, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials

Fortrea has agreed to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biological sample storage facility in Pflugerville, Texas. This strengthens Fortrea's end-to-end clinical development platform with integrated bioanalytical capabilities for both large and small molecules, while allowing Worldwide to focus on its growing advanced-stage development activities in oncology, neurosciences, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire

Fortrea 將收購 Worldwide Clinical Trials 的臨床藥理學部門及生物分析實驗室業務

Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling facility in Frugerville, Texas. The deal strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its rapidly growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.

09/03/2026, 3:52 AM • GlobeNewswire